bioAffinity Technologies, Inc. (BIAF)
NASDAQ: BIAF · Real-Time Price · USD
1.150
+0.080 (7.48%)
At close: Feb 18, 2026, 4:00 PM EST
1.199
+0.049 (4.29%)
After-hours: Feb 18, 2026, 7:03 PM EST
bioAffinity Technologies Revenue
bioAffinity Technologies had revenue of $1.45M in the quarter ending September 30, 2025, a decrease of -38.48%. This brings the company's revenue in the last twelve months to $6.78M, down -27.66% year-over-year. In the year 2024, bioAffinity Technologies had annual revenue of $9.36M with 269.68% growth.
Revenue (ttm)
$6.78M
Revenue Growth
-27.66%
P/S Ratio
0.11
Revenue / Employee
$118,890
Employees
57
Market Cap
5.17M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.36M | 6.83M | 269.68% |
| Dec 31, 2023 | 2.53M | 2.53M | 52,627.44% |
| Dec 31, 2022 | 4.80K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Inotiv | 514.03M |
| FONAR | 106.03M |
| Biodesix | 80.17M |
| Exagen | 63.60M |
| XWELL | 29.52M |
| Precipio | 22.80M |
| iSpecimen | 3.35M |
| Mainz Biomed | 659.94K |
BIAF News
- 1 day ago - Clinical Utility of bioAffinity Technologies' CyPath® Lung Test Demonstrated in Real-World Case Study - Business Wire
- 9 days ago - bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board - Business Wire
- 6 weeks ago - bioAffinity Technologies' Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation - Business Wire
- 2 months ago - bioAffinity Technologies' Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable - Business Wire
- 3 months ago - bioAffinity Technologies Reports Third Quarter 2025 Financial Results - Business Wire
- 3 months ago - bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume - Business Wire
- 4 months ago - bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases - Business Wire
- 4 months ago - bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025 - Business Wire